[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-brain-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-brain-tumor":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,123,157,186,226,255,286,307,330,358],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100479361","phase-1-targeting-pediatric-brain-tumors-and-relapsedrefractory-solid-tumors-with-sodium-glucose-cotransporter-2-inhibitors-sglt2i-100479361",false,"NCT05521984","Targeting Pediatric Brain Tumors and Relapsed\u002FRefractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)","Inclusion Criteria:\n\n* Diagnosis of a recurrent primary brain tumor with no curative therapy available OR diagnosis of relapsed\u002Frefractory solid tumor with no curative option and has trialed past a second line of therapy.\n* Measurable disease per the following:\n\n  * For patients with brain tumors: measurable disease pediatric Response Assessment in Neuro-Oncology Criteria (RANO) criteria\n  * For patients with solid tumors: measurable disease using response evaluation criteria in solid tumors (RECIST 1.1). Includes patients with diagnoses of relapsed or refractory sarcomas, neuroblastoma, and Wilms tumor. Other rare solid tumors can be discussed with study chair.\n* Life expectancy \\> 12 weeks.\n* Prior treatment with radiation alone, chemotherapy alone or combined radiation and chemotherapy is allowed.\n* Patient is between 6 and 29 years old (inclusive)\n* Patient is capable of swallowing whole pills\n* Normal bone marrow and organ function as defined below:\n\n  * Leukocytes ≥ 3,000\u002FmcL\n  * Absolute neutrophil count ≥ 1,500\u002Fmcl\n  * Platelets ≥ 100,000\u002Fmcl\n  * Total bilirubin ≤ 1.5 x IULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3.0 x IULN\n  * Creatinine ≤ IULN OR creatinine clearance ≥ 60 mL\u002Fmin\u002F1.73 m\\^2 for patients with creatinine levels above institutional normal\n  * Normal room air oxygenation must be documented. If room air oxygen saturation is less than 97%, a diffusion capacity of carbon monoxide (DLCO) of greater than 80%, must be demonstrated.\n* Karnofsky or Lansky performance score of ≥ 60\n* Patients of childbearing potential and their partners must agree to use two forms of acceptable contraception (including one barrier method) prior to study entry and for the duration of study participation. Should a female patient or partner of a male patient become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants. All patients and\u002For their parents or legal guardians must sign an IRB approved written informed consent document.\n\nExclusion Criteria:\n\n* Current or previous treatment with SGLT2i or thiazolidinedione.\n* Current use of high dose dexamethasone (exceeding 4 mg\u002Fday). Seven days prior to start of dapagliflozin, patients receiving dexamethasone must be on a stable or decreasing dose (≤ 0.1 mg\u002Fkg\u002Fday or maximum 4 mg\u002Fday). Note that it is preferred that patients not be on dexamethasone during the study.\n* A history of other malignancy with the exceptions of malignancies for which all treatment was completed at least 2 years before registration with no evidence of disease and locally treated skin squamous or basal cell carcinoma.\n* Type 1 diabetes or current insulin treatment.\n* History of stroke or transient ischemic attack (in the last 5 years).\n* HbA1c \\> 8.5%. The rationale is that this is the level that would require addition of insulin. However, insulin use is excluded in this study due to the increased risk of ketoacidosis.\n* Currently receiving any other investigational agents.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to dapagliflozin or other agents used in the study.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, peripheral arterial disease, ketoacidosis, severe kidney disease (estimated glomerular filtration rate eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m\\^2), symptomatic hypotension, and chronic\u002Ffrequent urinary tract infections or yeast infections.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of dapagliflozin.\n* Patients with HIV are eligible unless their CD4+ T-cell counts are \\\u003C 350 cells\u002FmcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.","ALL","6 Years","21 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a pilot phase Ib study of the safety of dapagliflozin (in addition to standard of care treatment) for the treatment of pediatric patients with recurrent brain tumors and relapsed\u002Frefractory solid tumors. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious as an adjunct to front-line chemotherapy assessed by decreased tumor markers mediated by its pleiotropic metabolic effects.",[26,27],"Pediatric Brain Tumor","Pediatric Solid Tumor","RECRUITING","2026-06-07",{"date":31,"type":32},"2026-06-10","ACTUAL",{"date":34,"type":32},"2023-04-03",{"date":36,"type":20},"2031-06-30",{"name":38,"class":39},"Washington University School of Medicine","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":17,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":86,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100355699","phase-1-hsv-g207-in-children-with-recurrent-or-refractory-cerebellar-brain-tumors-100355699","NCT03911388","HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Inclusion Criteria:\n\n* Age ≥ 36 months and \\\u003C 22 years\n* Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid\u002Frhabdoid tumor, germ cell tumor, or other high-grade malignant tumor) which is progressive or recurrent despite standard care including surgery, radiotherapy, and\u002For chemotherapy. A pathologically proven secondary malignant cerebellar tumor without curative treatment options is eligible.\n* Lesion must be ≥ 1.0 cm ≤ 3.0 cm in diameter and surgically accessible as determined by MRI. Larger tumors may be surgically debulked and treated if ≤ 3.0 cm after debulking\n* Patients must have fully recovered from acute treatment related toxicities of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study.\n* Myelosuppressive chemotherapy: patients must have received their last dose at least 3 weeks prior (or at least 6 weeks if nitrosurea)\n* Investigational\u002FBiologic agents: patients must have recovered from any acute toxicities potentially related to the agent and received last dose ≥ 7 days prior to entering this study (this period must be extended beyond the time during which adverse events are known to occur for agents with known adverse events ≥ 7 days). For viral therapy, patients must have received viral therapy ≥ 3 months prior to study entry and have recovered from all acute toxicities potentially related to the agent.\n* Monoclonal antibodies: The patient must have received last dose ≥ 21 days prior.\n* Radiation: Patients must have received their last fraction of craniospinal radiation (\\>24 Gy) or total body irradiation ≥ 3 months prior to study entry. Patients must have received focal radiation to symptomatic metastatic sites or local palliative radiation ≥ 28 days prior to study entry.\n* Autologous bone marrow transplant: Patients must be ≥ 3 months since transplant prior to study entry.\n* Normal hematological, renal and liver function (absolute neutrophil count \\> 1000\u002Fmm3, platelets \\> 100,000\u002Fmm3, prothrombin time (PT) or partial thromboplastin time (PTT) \\\u003C 1.3 x control, creatinine within normal institutional limits OR creatinine clearance \\>60 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal, total bilirubin \\\u003C 1.5 mg\u002Fdl, transaminases \\\u003C 3 times above the upper limits of the institutional norm)\n* Patients \\\u003C 16 years, Modified Lansky performance score ≥ 60; patients ≥ 16 years, Karnofsky performance score ≥ 60\n* Patient life expectancy must be at least 8 weeks\n* Written informed consent in accordance with institutional and FDA guidelines must be obtained from patient or legal guardian\n\nExclusion Criteria:\n\n* Any treatment outside the allowable guidelines outlined in section 5.1.\n* Diffuse, widespread, abnormal tumor pattern involving 3 or more lobes of the brain\n* Acute infection, granulocytopenia or medical condition precluding surgery\n* Pregnant or lactating females\n* Diagnosis of encephalitis or CNS infection \\\u003C 3 months prior, or receiving ongoing treatment for encephalitis, CNS infection or multiple sclerosis\n* Tumor involvement which would require ventricular or brainstem inoculation or would require access through a ventricle in order to deliver treatment\n* Required steroid increase within 1 week prior to G207 inoculation or patients requiring \\>2 mg of dexamethasone daily\n* Known HIV seropositivity\n* Concurrent therapy with any drug active against HSV (acyclovir, valacyclovir, penciclovir, famciclovir, gancyclovir, foscarnet, cidofovir) or any immunosuppressive drug therapy (except dexamethasone or prednisone).\n* Other current malignancy\n* Concurrent anticancer or investigational drug","3 Years",{"count":50,"type":20},24,[23],"This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.\n\nFunding Source- FDA OOPD",[54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,26,84,85],"Neoplasms, Brain","Glioblastoma Multiforme","Glioblastoma of Cerebellum","Neoplasms","Astrocytoma","Astrocytoma, Cerebellar","Neuroectodermal Tumors","Neuroectodermal Tumors, Primitive","Cerebellar PNET, Childhood","Cerebellar Neoplasms","Cerebellar Neoplasms, Primary","Cerebellar Neoplasm, Malignant","Cerebellar Neoplasm Malignant Primary","Neoplasm Metastases","Neoplasm Malignant","Neoplasms, Neuroepithelial","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms, Glandular and Epithelial","Neoplasms, Nerve Tissue","Central Nervous System Neoplasms, Primary","Central Nervous System Neoplasms, Malignant","Nervous System Neoplasms","Neoplasms by Site","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Medulloblastoma Recurrent","HSV","Virus","Nervous System Cancer","Primitive Neuroectodermal Tumor (PNET) of Cerebellum",[87,88,55,89,90,91,92,93,94,95,96,97,98,99,100,101,57,102,103,104,105,106,107,108,109,83,82,110,111,112],"Brain Tumor, Recurrent","Glioma","Gliosarcoma","Medulloblastoma","Anaplastic Astrocytoma","Oligodendroglioma","Rhabdoid Tumor","Ependymoma","Germ Cell Tumor","Choroid Plexus Carcinoma","Cerebral Primitive Neuroectodermal Tumor","Giant Cell Glioblastoma","Atypical teratoid\u002Frhabdoid tumor","Secondary Malignant Cerebellar Tumor","Embryonal Tumor","Oncolytic Virus Therapy","Virotherapy, Oncolytic","Immunotherapy","Central Nervous System Agents","Antineoplastic Agents","Pediatric","Pediatrics","Oncolytic","Herpes Virus","G207","Oncolytic Herpes Virus","2026-05-13",{"date":115,"type":32},"2026-05-15",{"date":117,"type":32},"2019-09-12",{"date":119,"type":20},"2027-09-01",{"name":121,"class":39},"M.D. Anderson Cancer Center",3,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":15,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":151,"leadSponsor":153,"locationsCount":156},"100635877","effectiveness-of-a-visual-telerehabilitation-program-on-visual-perception-in-children-adolescents-and-young-adults-with-hemianopsia-consecutive-to-a-brain-tumour-100635877","NCT07558395","Effectiveness of a Visual Telerehabilitation Program on Visual Perception in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour","REVIIH-BT","Inclusion Criteria:\n\n* Male and Female\n* 10 - 40 years old\n* Diagnosed hemianopsia (\\>12 months)\n* History of diagnosis brain tumour\n* Being stable for the tumour for \\> 6 months (either on therapy or not)\n* Visual acuity ≤ 0.7 LogMAR\n* Ability to follow the visual and auditory stimuli and training instructions\n* Home WiFi access\n* Ability to attend all on site visits\n* Affiliation to the Social Security or beneficiary of such social protection\n\nExclusion Criteria:\n\n* Age\\\u003C 10 years old of \\> 40 years old\n* Ocular disease\n* Inability to perform during testing or training\n* 3 consecutive VRISE scores \\\u003C 25 at inclusion\n* History of vertigo\n* Prior vision rehabilitation interventions\n* Recreational or medicinal consumption of psychoactive drugs\n* Persons under court protection\n* Interpupillary distance \\\u003C 54mm","10 Years","40 Years",{"count":133,"type":20},120,[135],"NA","Evaluate the efficiency of audiovisual stimulation in virtual reality for improving the visual perception of children, adolescents, and young adults with hemianopia resulting from pediatric brain tumors. These individuals can lose up to 50% of their visual field, significantly impacting their independence, mobility, and daily lives.",[138,139,140,26],"Hemianopsia","Virtual Reality","Visual Rehabilitation",[142,143,144,145],"brain tumor","pediatric","visual rehabilitation","virtual reality","NOT_YET_RECRUITING","2026-04-23",{"date":149,"type":32},"2026-04-30",{"date":115,"type":20},{"date":152,"type":20},"2029-09",{"name":154,"class":155},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",8,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":165,"sex":15,"minAge":166,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":21,"phases":170,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":40},"100496177","high-intensity-interval-exercise-in-young-adult-survivors-of-pediatric-brain-tumors-a-pilot-feasibility-study-100496177","NCT05740839","High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study","High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study (HYPE)","HYPE","Inclusion Criteria:\n\n* Written informed consent prior to any study-related procedures.\n* At time of study are a young adult, aged 18-45 years.\n* Histologically diagnosed brain tumor during childhood, or currently diagnosed with an IDH-mutant glioma (diagnosed \\> 18 years).\n* Are at least 2 years post tumor-directed therapy for pediatric brain tumor survivors, or at least 1 year since their most recent surgery, radiation or chemotherapy treatment for IDH-mutant glioma patients (or are deemed able to participate in the study based on the assessment of their treating physician). IDH-mutant glioma patients can participate while on maintenance therapy with an IDH inhibitor.\n* The effects of exercise on the developing fetus are unknown. For this reason, people of child-bearing potential must verify pregnancy status by providing first day of their last menstrual cycle and agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry. Should a person become pregnant or suspect that they are pregnant while participating on the trial, they should inform their treating physician immediately.\n* Medically cleared to participate in exercise by their referring physician or a certified clinical exercise physiologist.\n* If participants have a diagnosis of tumor-related epilepsy, they must have good seizure control, with no generalized seizures in the 6 months preceding enrollment.\n* Are without any other medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases.\n* Speak English and\u002For Spanish.\n* Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise\u002Fweek.\n* Does not smoke cigarettes or e-cigarettes (no smoking during the previous 12 months). Those who infrequently smoke in social settings will be included. Those who vape will also be included.\n* Willing to travel to DFCI for necessary data collection.\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Diagnosis of primary spinal cord tumor.\n* Pre-existing medical conditions such as uncontrolled tumor-related epilepsy, cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise.\n* Patients with evidence of progressive CNS or systemic cancer in the last 3 months.\n* People who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.\n* Actively on a weight loss diet.\n* Participate in more than 60 minutes of moderate or vigorous structured exercise\u002Fweek.\n* Currently and regularly smokes.\n* Unable to travel to DFCI for necessary data collection.\n* May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator.",true,"18 Years","45 Years",{"count":169,"type":20},30,[135],"The purpose of this study is to determine whether a 16-week virtual, home-based, high-intensity interval training (HIIT) exercise program will improve physical, cognitive, and emotional health among young adult survivors of pediatric brain tumors.\n\nThe names of the study interventions involved in this study are\u002Fis:\n\n* High-Intensity Interval Training (HIIT)",[26],[26,174,175,176],"Exercise Program","HIIT Program","Pediatric Brain Tumor Survivors","2026-02-23",{"date":179,"type":32},"2026-02-24",{"date":181,"type":32},"2023-12-04",{"date":183,"type":20},"2027-09-24",{"name":185,"class":39},"Dana-Farber Cancer Institute",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":15,"minAge":193,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":198,"conditions":199,"keywords":208,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":40},"100599631","phase-1-gpc2-car-t-cell-therapy-for-relapsed-or-refractory-medulloblastoma-in-children-and-young-adults-100599631","NCT07087002","GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults","Phase I Clinical Trial of GPC2 Chimeric Antigen Receptor T (GPC2-CAR T) Cells for Relapsed or Refractory Medulloblastoma in Children and Young Adults","Inclusion Criteria:\n\n1. Diagnosis: Histologically confirmed diagnosis of medulloblastoma or other primary CNS embryonal tumor according to 2021 CNS WHO Classification (5th edition)\n\n   * Other acceptable CNS embryonal tumors include:\n   * Embryonal Tumor with Multilayered Rosettes (ETMR)\n   * Pineoblastoma\n   * Atypical Teratoid\u002FRhabdoid Tumor (ATRT) of the CNS\n   * CNS neuroblastoma, FOXR2-activated\n   * CNS Embryonal Tumor NOS\n2. Recurrent\u002FRefractory Disease: History of relapsed and\u002For recurrent disease defined as tumor progression or recurrence following initial diagnosis and upfront treatment with curative intent, or failure to achieve disease control with standard curative-intent therapy.\n3. GPC2 Positive: H-score ≥ 100 by IHC staining performed on the (Prescreening Protocol IRB-78780, PI: Katherine Ryan, DO) at Stanford Clinical Anatomic Pathology Lab for GPC2 from a tumor sample any time since initial diagnosis.\n4. Evaluable Disease: Evaluable disease as per radiographic findings and\u002For positive cerebrospinal fluid cytology within 28 days of enrollment.\n5. Patients with VP shunts: Patients with pre-existing ventriculo-peritoneal (VP) shunt devices must have a programmable shunt device to enroll on this study. A VP shunt is not a requirement for this study.\n6. Prior therapy: No limit to the number of prior treatment regimens. Toxicities due to prior therapy must be stable or recovered to ≤ Grade 1 (except for clinically non-significant toxicities such as alopecia, nutritional support measures, electrolyte abnormalities, or those not impacting the investigator's ability to assess treatment emergent toxicities).\n\n   At time of enrollment, subjects are on track to meet the required therapy wash out period(s) prior to apheresis.\n\n   a. At least 6 weeks following craniospinal radiation therapy. i. At least 14 days wash-out needed following small volume radiotherapy (i.e., Stereotactic Radiosurgery (SRS)).\n\n   b. At least 21 days or 5 half-lives (whichever is shorter) must have elapsed since any prior systemic therapy, except for systemic inhibitory\u002Fstimulatory immune checkpoint therapy, which requires 5 half-lives.\n\n   c. At least 28 days following bevacizumab treatment. d. At least 30 days following any investigational drug. e. At least 12 weeks following systemic inhibitory or stimulatory immune checkpoint therapy.\n7. Age: ≥ 12 months to ≤ 30 years of age at time of enrollment The first 3 subjects treated with GPC2-CAR T cells must be ≥ 3 years old at time of infusion\n8. Performance Status: Subjects ≥ 16 years of age must have Karnofsky ≥ 60%. Subjects \\\u003C 16 years of age must have Lansky scale 60%; or ECOG performance status ≤ 2 (see Section 11.3).\n9. Normal Organ and Marrow Function \\[supportive care is allowed per institutional standards, i.e., filgrastim, transfusion\\]\n\n   1. Hemoglobin ≥ 8 g\u002FdL\n   2. Absolute Neutrophil Count (ANC) ≥ 1,000\u002FμL\n   3. Platelet count ≥ 75,000\u002FμL, with no platelet transfusion within 96 hours prior to enrollment\n   4. Absolute lymphocyte count (ALC) ≥ 150\u002FμL\n   5. PT\u002FINR, PTT ≤ 1.5 x ULN for age\n\n      Adequate renal, hepatic, cardiac, and pulmonary function defined as:\n   6. Serum creatinine \\\u003C 1.5 x ULN for age and gender, OR creatinine clearance or GFR (radioisotope or iothalamate) ≥ 70 mL\u002Fmin\u002F1.73 m2\n   7. Serum ALT or AST ≤ 3x ULN\n   8. Total bilirubin ≤ 1.5 mg\u002FdL, unless subject has Gilbert's Syndrome\n   9. Cardiac ejection fraction ≥ 45%\n   10. No evidence of physiologically significant pericardial effusion as determined by an ECHO\n   11. No clinically significant ECG findings\n   12. No clinically significant pleural effusion\n   13. Pulse oximetry ≥ 92% on room air, OR forced vital capacity ≥ 50% of predicted value\n10. Not Pregnant: Females of childbearing potential must have a negative pregnancy test.\n11. Contraception: Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative regimen or for as long as CAR T cells are detectable in peripheral blood.\n12. Must provide informed consent. All subjects ≥ 18 years of age must be able to give informed consent. For subjects \\\u003C18 years old or adults with limited decision-making capacity, their legal authorized representative (LAR) (i.e., parent or guardian) must give informed consent. Pediatric subjects will be included in age-appropriate discussion and assent will be obtained for those \\> 7 years of age, when appropriate. If a minor becomes of age during participation of this study, he\u002Fshe will be asked to reconsent as an adult.\n\nExclusion Criteria\n\n1. Any patient with metastatic disease OUTSIDE the CNS.\n2. Unwilling or unable, in the investigator's judgement, to have a CSF reservoir (Ommaya or Rickham) placed. Does not apply to subjects who have a pre-existing device suitable for ICV delivery of CAR T cells and ICP monitoring.\n3. Clinical evidence of active\u002Fon-going significant increased intracranial pressure (i.e., impending herniation) or uncontrolled seizures.\n4. Prior receipt of a chimeric antigen receptor (CAR)-based therapy.\n5. Currently receiving anticoagulation therapy.\n6. Known history of infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive).\n\n   EXCEPTION: A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and\u002For nucleic acid testing.\n7. Pregnancy or breastfeeding in a postpartum female.\n8. Known sensitivity or allergy to any agents\u002Freagents used in this study.\n9. History of prior other malignancy. EXCEPTION: Previously diagnosed and definitively treated more than 5 years prior to enrollment or whose prognosis is deemed good enough to not warrant surveillance.\n10. Primary immunodeficiency or history of autoimmune disease (e.g., Crohn's, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression\u002Fsystemic disease modifying agents within the last 2 years.\n11. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.\n12. Significant medical diseases or poorly controlled conditions that, in the judgement of the investigator, put the subject at an unacceptable risk of complications, including but not limited to: uncontrolled diabetes mellitus, chronic obstructive pulmonary disease, pulmonary fibrosis, clinically significant inflammatory disorders, immunodeficiency (e.g., HIV infection), immunocompromised for reasons other than malignancy (e.g., chronic corticosteroid therapy or other immunosuppressive therapy), renal failure including patients requiring dialysis, or clinically significant liver dysfunction.\n13. In the Investigator's judgment, the subject or parents\u002Fcaregivers (as required) will not be able to comply with the study procedures outlined in the study protocol including follow-up visits.","1 Year","30 Years",{"count":196,"type":20},18,[23],"This is a single-site, open-label Phase 1 clinical trial evaluating the feasibility, safety, and preliminary activity of autologous GPC2-targeted chimeric antigen receptor (CAR) T cells administered via intracerebroventricular (ICV) infusion in children and young adults with relapsed or refractory medulloblastoma or other eligible Central Nervous System (CNS) embryonal tumors.",[90,200,201,202,26,203,204,205,206,207],"Central Nervous System Embryonal Tumor","Refractory Medulloblastoma","Recurrent Medulloblastoma","Embryonal Tumor With Multilayered Rosettes (ETMR)","Pineoblastoma","Atypical Teratoid\u002FRhabdoid Tumor (ATRT) of the CNS","CNS Neuroblastoma","FOXR2-activated",[209,210,211,212,104,90,213,214,215,204,205,216,207],"GPC2-CAR T cells","Chimeric Antigen Receptor T cells","Intracerebroventricular CAR T","Pediatric CNS tumors","Refractory brain tumors","T cell therapy","Embryonal Tumor with Multilayered Rosettes (ETMR)","CNS neuroblastoma","2026-01-26",{"date":219,"type":32},"2026-01-27",{"date":221,"type":32},"2025-08-28",{"date":223,"type":20},"2027-08",{"name":225,"class":39},"Stanford University",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":15,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":21,"phases":236,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":254},"100585831","phase-2-a-multicenter-study-to-assess-the-feasibility-of-5-aminolevulinic-acid-5-ala-in-pediatric-brain-tumor-patients-100585831","NCT06907485","A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients","A Multicenter Study to Assess the Feasibility of Gleolan (ALA \u002F Aminolevulinic Acid HCl) in Pediatric Brain Tumor Patients After Delayed Administration","Inclusion Criteria:\n\n1. Subjects included in this trial must have had an MRI documentation of \"a new or recurrent primary pediatric brain tumor\" for which resection is indicated and has been planned.\n2. The anticipated histology at resection will be \"newly diagnosed\" or \"recurrent\": pilocytic astrocytoma, pleomorphic xanthoastrocytoma (PXA), ganglioglioma, diffuse neuroepithelial tumor (DNET), astrocytoma, oligodendroglioma, ependymoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic ependymoma, anaplastic ganglioglioma, anaplastic PXA, PNET, ATRT, or medulloblastoma.\n3. Male or Female Age 2-17 years and 182 days\n4. Subjects must have normal organ and marrow function as defined below:\n\n   Leukocytes \\>3,000\u002FmL Platelets \\>100,000\u002FmL Total bilirubin Below upper limit of normal (ULN) AST (SGOT)\u002FALT (SGPT)\u002F GGT \\\u003C2.5 X institutional age-specific ULN Creatinine Below ULN\n\n   OR\n\n   Creatinine Clearance \\>60 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional age-specific normal as defined per institution.\n5. The effects of 5-ALA on the developing human fetus are unknown. A pregnancy test will be performed for all young women of childbearing ability prior to surgery (see Exclusion Criteria below). Should a young woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n6. Ability for patient\u002Fpatient's guardian to understand and the willingness to sign a written informed consent document. In appropriate cases, assent of pediatric patients will be obtained. Translation will be provided as appropriate.\n7. Inclusion of Women and Minorities: Both males and females and members of all ethnic groups are eligible for this trial.\n\nExclusion Criteria:\n\n1. Patients who meet inclusion criteria but are unable to swallow 5-ALA solution.\n2. Patients with radiographic tumors of the brain stem as assessed by MRI.\n3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-ALA. Patients should refrain from use of other potential phototoxic substances (e.g., tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts) for 24 h.\n4. Personal or family history of porphyria.\n5. Uncontrolled concurrent illness including, but not limited to: ongoing or active infection, heart disease, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 5-ALA breastfeeding should be discontinued if the mother is treated 5-ALA.\n6. Young women who are pregnant or become pregnant will be excluded from the trial as it is unknown if 5-ALA is teratogenic or has abortifacient effects. A pregnancy test will be performed on all young women who are s\u002Fp menstruation prior to entering study.\n7. Prior history of GI perforation, diverticulitis, and\u002For peptic ulcer disease.","2 Years","17 Years",{"count":19,"type":20},[237],"PHASE2","This clinical trial focuses on pediatric patients aged 2 up to 18 years of age with a new or recurrent pediatric brain tumor, suspected to be either a high-grade or low-grade glioma, and scheduled for surgical removal. 5-aminolevulinic acid (5-ALA) is FDA-approved for improving brain tumor visualization in adults during surgery through fluorescence, enabling more complete removal of the tumor. This study aims to evaluate the feasibility of administering 5-ALA to pediatric brain tumor patients and to assess the quality of tumor fluorescence during surgery in this patient population.\n\nFor the clinical trial, the patient will orally ingest 5-ALA 6 to 12 hours before brain surgery. All study participants will be provided standard medical care for removal of the brain tumor. All children enrolled in the study will be closely monitored prior to, during, and after surgery to ensure there are no reactions to the study drug. 5-ALA can make the patient more sensitive to sunlight and direct indoor lighting, referred to as photosensitivity, and can cause a sunburn-type reaction. It is for this reason that patients will be kept in subdued light conditions for 48 hours following surgery. Study participation starts once the patient is enrolled in the study until 6-month post-surgery.",[26],[241,242,243,244,107],"Aminolevulinic Acid (ALA)","Gleolan®","Fluorescence-Guided Resection","Brain Tumor","2026-01-20",{"date":247,"type":32},"2026-01-21",{"date":249,"type":20},"2026-08",{"date":251,"type":20},"2028-08",{"name":253,"class":39},"Costas Hadjipanayis",2,{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":15,"minAge":263,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":267,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":254},"100617648","survivors-journey-100617648","NCT07321353","Survivors Journey+","Online Problem-Solving Intervention for Brain Tumor Survivors: A Two-site, Two-arm Pilot Randomized Controlled Trial","SJ","Inclusion Criteria:\n\n* a diagnosis of a pediatric intracranial tumor\n* tumor-directed treatment completed \\> 12 months ago (treatment included: surgery, radiation, or chemotherapy)\n* lives with parent\u002Fguardian(s)\n* language: English must be the primary spoken language in the home\n\nExclusion Criteria:\n\n* history of tuberous sclerosis or neurofibromatosis\n* treatment \\\u003C 12 months ago and\u002For treatment did not include surgery, radiation, or chemotherapy\n* history of psychiatric hospitalization\n* resides outside of the family home\n* history of autism, reactive attachment disorder, psychosis, or other psychiatric diagnoses\u002Fconditions associated with significant risk of harm to self or others per caregiver\n* English is not the primary language spoken in the home","15 Years","25 Years",{"count":266,"type":20},72,[135],"The main goal of this pilot randomized controlled trial is to learn if an online program called \"Survivors Journey\" (SJ+) can help teens and young adults, ages 15-25, who are Pediatric Brain Tumor Survivors (PBTS), and their caregivers, manage everyday challenges better by using skills like problem-solving and coping skills. The main questions it aims to answer are:\n\n* Is the SJ+ program rated as feasible (\\>50% enrollment rate and \\>75% retention rate) and acceptable (\\>80% satisfaction rate) by PBTS and their caregivers?\n* Does the SJ+ program have better outcomes in improving PBTS and caregiver wellbeing in comparison to an internet resource comparison (IRB) made for PBTS and their families? Participants will be randomized into two groups: one group will be given access to the online SJ+ program and receive weekly online coaching sessions, and the other group will be given access to an IRC. Outcomes will be assessed at baseline, treatment completion (\\~ 3 months post-baseline), and at follow-up six months post-baseline. These outcomes include quality of life, internalizing symptoms, performance-based executive function skills, depression, and family impact.",[26],[271,272,273,274,275,276],"pediatric brain tumor survivors","online learning","Adolescent young adult","Family","Digital","Problem Solving","2025-12-22",{"date":279,"type":32},"2026-01-07",{"date":281,"type":32},"2025-08-01",{"date":283,"type":20},"2028-09",{"name":285,"class":39},"Children's Hospital Medical Center, Cincinnati",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":15,"minAge":193,"maxAge":234,"enrollmentInfo":292,"targetDuration":4,"studyType":294,"phases":4,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":40},"100591494","evaluation-of-the-neurologic-assessment-in-pediatric-neuro-oncology-pnano-100591494","NCT06981156","Evaluation of the Neurologic Assessment in Pediatric Neuro-Oncology (pNANO)","Inclusion Criteria:\n\n* greater than or equal to 1 year old\n* must be seen in the pediatric clinic\n* Radiographic or histologic confirmation of a brain or spine tumor at the time of initial diagnosis\n* Patient or parent\u002Fguardian must be able to understand the consent and be willing to sign a written informed consent document according to institutional guidelines.\n\nExclusion Criteria:\n\n* none specified",{"count":293,"type":20},75,"OBSERVATIONAL","This study aims to investigate a neurologic exam scale to provide an objective and more standard way to assess tumor response in pediatric patients with brain and spinal cord tumors.",[26,297],"Pediatric Spine Tumor","2025-07-02",{"date":300,"type":32},"2025-07-04",{"date":302,"type":32},"2025-05-13",{"date":304,"type":20},"2027-01",{"name":306,"class":39},"University of Wisconsin, Madison",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":166,"enrollmentInfo":314,"targetDuration":316,"studyType":294,"phases":4,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":40},"100588618","non-helium-magnetoencephalography-in-pediatric-brain-tumors-100588618","NCT06943742","Non-Helium Magnetoencephalography in Pediatric Brain Tumors","Non-Helium Magnetoencephalography for Clinical Management of Pediatric Brain Tumors : An Observational Cohort Study","Inclusion Criteria:\n\n* Age range: 3-18 years old;\n* Clinically diagnosed with brain tumor;\n* Capable of cooperating with magnetoencephalography evaluation and recording.\n\nExclusion Criteria:\n\n* Patients with serious comorbidities or neurological or psychiatric disorders that affect magnetoencephalography examination.\n* Patients using drugs that affect central nervous system function;\n* Patients who are not suitable for surgical procedures;\n* Patients with progressive neurological disorders.",{"count":315,"type":20},100,"12 Months","This observational study aims to evaluate the effectiveness of magnetoencephalography (MEG) in the preoperative assessment of pediatric brain tumors, particularly in determining the extent of resection, and compare it with computed tomography (CT) and magnetic resonance imaging (MRI).\n\nThe main questions this study aims to answer are:\n\nWhat is the consistency between MEG and CT\u002FMRI in localizing pediatric brain tumors? What is the clinical efficacy of MEG in determining the extent of resection of pediatric brain tumors preoperatively?\n\nParticipants will:\n\nUndergo both MEG and CT\u002FMRI examinations for preoperative assessment, and the extent of tumor resection will be determined by the comprehensive results of the above examinations.\n\nBe followed up with MEG and CT\u002FMRI at 1, 3, and 6 months after surgery, along with neurological and quality-of-life assessments.",[26],[320,26],"Magnetoencephalography","2025-04-22",{"date":323,"type":32},"2025-04-24",{"date":325,"type":32},"2024-11-05",{"date":327,"type":20},"2027-12-31",{"name":329,"class":39},"Guangzhou Women and Children's Medical Center",{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":15,"minAge":338,"maxAge":339,"enrollmentInfo":340,"targetDuration":4,"studyType":21,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":40},"100479896","feasibilityacceptability-of-attentional-control-training-in-survivors-100479896","NCT05528939","Feasibility\u002FAcceptability of Attentional-Control Training in Survivors","FAACTS: Feasibility\u002FAcceptability of Attentional-Control Training in Survivors","FAACTS","Inclusion Criteria:\n\n* Aged 8-16 years at time of screening.\n* History of diagnosis of acute lymphoblastic leukemia (ALL) or brain tumor (BT).\n* At least 1 year from completion of planned therapy and stable from a disease standpoint.\n* Participating child and caregiver are fluent in spoken English.\n* Availability of a caregiver who is willing and capable of providing support and supervision during cognitive training.\n* Participating child is either not taking any prescribed stimulant medication for attention difficulties or has been prescribed a stable dose of stimulant medication for attention difficulties for at least 30 days prior to enrollment.\n* Only patients with a T-score ≥ 75th percentile on the CPT-3 Omission Errors scale or on the BRIEF-2 Cognitive Regulation Index will be randomized.\n\nExclusion Criteria:\n\n* A history of photosensitive seizures.\n* A motor, visual, or auditory handicap that prevents computer use.\n* A mental health condition that precludes, or takes treatment precedence over, participation in the cognitive training.\n* Participants identified during the baseline assessment as having a full-scale IQ \\\u003C 80, as estimated by WASI-II (Vocabulary and Matrix Reasoning), will not be randomized.","8 Years","16 Years",{"count":341,"type":20},50,[135],"This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ages 8-16 who are \\> 1 year from the end of therapy.",[345,346,26,347,348],"Pediatric Cancer","Pediatric ALL","Attention Difficulties","Cognitive Deficit in Attention","2025-01-08",{"date":351,"type":32},"2025-01-10",{"date":353,"type":32},"2023-06-14",{"date":355,"type":20},"2025-08-31",{"name":357,"class":39},"Children's National Research Institute",{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":15,"minAge":366,"maxAge":166,"enrollmentInfo":367,"targetDuration":4,"studyType":21,"phases":369,"briefSummary":370,"conditions":371,"keywords":375,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":40},"100575288","the-flame-cognitive-rehabilitation-study-for-childhood-brain-tumour-100575288","NCT06770335","The FLaME Cognitive Rehabilitation Study for Childhood Brain Tumour","Strategy-based Cognitive Rehabilitation with Integrated Fatigue Management for Patients with Paediatric Brain Tumour (PBT): an Acceptability and Feasibility Study of the Fatigue, Learning and Memory Enrichment (FLaME) Intervention","FLaME","Inclusion Criteria:\n\n1. Age range: 7 years to 17 years, 11 months.\n2. Received diagnosis and\u002For treatment\u002Fsurveillance at GOSH for a childhood tumour that involved the CNS (brain) and\u002For oncology treatment to brain.\n3. Received or receiving a neuropsychological assessment\u002Fconsultation at GOSH over the course of the study period or in the 48 months prior to the study period, or under active surveillance with the neuro-oncology multidisciplinary team during the study period.\n4. At least 6 months post-diagnosis\u002Facute treatment (surgery and\u002For radiotherapy), and 3 months post-return to school, with stable disease.\n5. One or more scores outside of normal limits (i.e. 1 SD above or below the mean in the direction indicating difficulty) in at least one neuropsychological domain (on performance-based tests or questionnaire-based rating scales).\n6. Report impairment (z-score \\> -0.67) in fatigue on one or more subscales of the PedsQL Multidimensional Fatigue Scale.\n7. Capacity\u002Fcompetence of patient or parent\u002Fcarer to provide informed\n\nExclusion Criteria:\n\n1. Completed or having another targeted formal psychological intervention for cognitive rehabilitation or fatigue in the past 6 months.\n2. Sensorimotor (e.g., visual-motor) impairment only on neuropsychological assessment without additional cognitive difficulty.\n3. Current substance misuse from self-report.\n4. Currently receiving formal psychiatric care for a diagnosed mental health disorder (including active suicidal ideation), excluding ADHD treatment (if a child has a diagnosis of ADHD they should be treated).\n5. Intellectual Disability based on a standard score of more than 2 standard deviations below the mean on a general adaptive behaviour composite and, where available, the General Ability Index of intellect.\n6. Patient and parent\u002Fcarer is unable to communicate verbally and in written form in English.","7 Years",{"count":368,"type":20},36,[135],"Medical treatments have improved survival rates for children with brain tumours. However, most children experience long-term difficulties with 'cognition' (thinking skills such as memory and paying attention) and cognitive fatigue (excessive mental tiredness) after treatment. Thinking difficulties and fatigue can affect a child's ability to learn, and their social and emotional wellbeing. National guidance recommends treatment called 'cognitive rehabilitation' which teaches skills to improve or manage cognitive difficulties. Families often request this, but it is not usually available due to little research. Fatigue may also get in the way of children using and benefiting from cognitive rehabilitation. No research study has offered a fatigue treatment for children recovering from brain tumours. The study aims to see if it is practical and helpful to families to provide cognitive rehabilitation for children affected by brain tumours. The treatment focuses on strategies to help cognition. The investigators will see if adding strategies to manage fatigue helps. The study will include thirty-six 7-17-year-olds who have been treated for brain tumour at Great Ormond Street Hospital. All participants will have had an assessment describing cognitive strengths and weaknesses as part of usual care. Participants will be randomly allocated to one of three groups: 1) cognitive rehabilitation with fatigue management (12 weeks), 2) cognitive rehabilitation only (6 weeks), or 3) usual care. Each child and their carer will complete questionnaires before, during, and after the treatment, and an interview at the end of the treatment. This information will help the researchers see if families find the treatment helpful and practical to take part in, and if adding fatigue strategies is beneficial. Researchers will look at information such as the number of appointments attended, feedback about the treatment, and information about fatigue levels, cognition, and wellbeing. The findings will be used to develop a UK-wide study.",[372,373,374,26],"Childhood Brain Tumor","Childhood Brain Tumors","Pediatric Brain Neoplasms",[376,377,378,379,380,381,382,383,384],"Paediatric brain tumour","cognitive rehabilitation","cognition","fatigue","feasibility","acceptability","neuropsychology","neurocognitive","childhood brain tumour","2025-01-07",{"date":387,"type":32},"2025-01-13",{"date":389,"type":20},"2025-03-10",{"date":391,"type":20},"2026-12-31",{"name":393,"class":39},"Great Ormond Street Hospital for Children NHS Foundation Trust"]